AI Science Tracker

An Integrated Deep Learning and Molecular Dynamics Simulation-Based Screening Pipeline Identifies Inhibitors of a New Cancer Drug Target TIPE2.

Chinese Academy of Sciences; Shenzhen Institutes of Advanced Technology · 23 Nov 2021 · medicine

Discovery

An Integrated Deep Learning and Molecular Dynamics Simulation-Based Screening Pipeline Identifies Inhibitors of a New Cancer Drug Target TIPE2.

Source check: Source checked. Not independent scientific confirmation.

Finding: A hybrid deep-learning, docking and molecular-dynamics screen nominated TIPE2 ligands. Biolayer interferometry tested four: UM-164 bound at Kd 4.97 μM, while three alternatives showed much weaker reported binding. A PIP2 competition assay does not establish cancer-treatment efficacy.

Technology: DFCNN dense fully connected neural network

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
DFCNN and DeepBindBC binding predictors, docking and molecular-dynamics simulations prioritized compounds for experimental TIPE2 binding and PIP2-competition assays.
Test and result
BLI tested four selected compounds: UM-164 Kd 4.97 μM, golvatinib about 189 μM and fedratinib about 298 μM. FIIN-3 was described as lacking reactivity; the discussion’s approximately 0.858 M fit is not evidence of appreciable binding. A separate UM-164 competition assay reduced TIPE2–PIP2 binding.
Limitation / still unknown
The assays establish biochemical binding and in-vitro competition only, not cellular target engagement or treatment efficacy. The paper's conclusion calls UM-164 low-nanomolar, but the reported BLI Kd is 4.97 μM.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.3389/fphar.2021.772296

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 18 Nov 2026. Review scope: Frontiers primary Methods on DFCNN/DeepBindBC and Results/Discussion on BLI binding, competition, and internal affinity inconsistencies..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.